Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Quest Diagnostics, Inc shares valued at $278,525 were sold by KUPPUSAMY KARTHIK on Oct 28 ’24. At $156.92 per share, KUPPUSAMY KARTHIK sold 1,775 shares. The insider’s holdings dropped to 9,734 shares worth approximately $1.51 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, KUPPUSAMY KARTHIK purchased 1,775 shares, netting a total of over 278,450 in proceeds.
Before that, PREVOZNIK MICHAEL E had sold 32,551 shares from its account. In a trade valued at $5,044,516, the SVP & General Counsel traded Quest Diagnostics, Inc shares for $154.97 each. Upon closing the transaction, the insider’s holdings decreased to 32,551 shares, worth approximately $5.96 million.
As published in a research note from Robert W. Baird on October 23, 2024, Quest Diagnostics, Inc [DGX] has been rated up from a Neutral to an Outperform and the price target has been revised to $182 from $157. As of July 10, 2024, Citigroup has increased its “Neutral” rating to a “Buy” for DGX. Earlier on February 26, 2024, Leerink Partners initiated its rating. Their recommendation was “a Market perform” for DGX stock.
Analyzing DGX Stock Performance
During the last five days, there has been a drop of approximately -2.00%. Over the course of the year, Quest Diagnostics, Inc shares have jumped approximately 12.29%. Shares of the company reached a 52-week high of $160.95 on 10/24/24 and a 52-week low of $123.04 on 02/01/24. A 50-day SMA is recorded $153.34, while a 200-day SMA reached $140.37. Nevertheless, trading volume fell to 0.87 million shares from 0.66 million shares the previous day.
Support And Resistance Levels for Quest Diagnostics, Inc (DGX)
According to the 24-hour chart, there is a support level at 153.95, which, if violated, would cause prices to drop to 153.06. In the upper region, resistance lies at 156.06. The next price resistance is at 157.28. RSI (Relative Strength Index) is 54.73 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 2.46, which suggests the price will increase in the coming days. Percent R is at 43.59%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
